FC
NVO

Farringdon Capital’s Novo Nordisk NVO Stock Holding History

Farringdon Capital’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,598
Closed -$426K – 355
2026
Q1 		$426K Buy
11,598
+2,064
+22% +$97.8K 0.09% 241
2025
Q4 		$485K Sell
9,534
-2,662
-22% -$136K 0.12% 228
2025
Q3 		$677K Buy
+12,196
New +$714K 0.17% 178

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Farringdon Capital's NVO Position: Q2 2026 in Review

Farringdon Capital sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 11,598 shares — an estimated $426K sold.

Farringdon Capital first reported a position in NVO in Q3 2025 and held it in 3 quarters. The position peaked at $677K in Q3 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Farringdon Capital reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
  • Farringdon Capital sold 11,598 Novo Nordisk shares in Q2 2026, an estimated $426K.
  • Farringdon Capital first reported a position in Novo Nordisk in Q3 2025 and held it in 3 quarters.
  • Farringdon Capital's Novo Nordisk position peaked at $677K in Q3 2025.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Farringdon Capital's 13F filing for Q2 2026, filed 12 Aug 2026.